Unique ID issued by UMIN | UMIN000021303 |
---|---|
Receipt number | R000024520 |
Scientific Title | Feasibility of Cytoreductive Prostatectomy in Men Newly Diagnosed with Metastatic Prostate Cancer |
Date of disclosure of the study information | 2016/04/01 |
Last modified on | 2020/08/20 11:00:05 |
Feasibility of Cytoreductive Prostatectomy in Men Newly Diagnosed with Metastatic Prostate Cancer
Feasibility of Cytoreductive Prostatectomy
Feasibility of Cytoreductive Prostatectomy in Men Newly Diagnosed with Metastatic Prostate Cancer
Feasibility of Cytoreductive Prostatectomy
Japan | Asia(except Japan) | North America |
metastatic prostate cancer
Urology |
Malignancy
NO
To determine the safety and feasibility of cytoreductive prostatectomy in men with newly diagnosed clinical T1-3N1M0 or T1-3N0M1a-b prostate cancer.
Safety,Efficacy
Confirmatory
Pragmatic
Phase I,II
the rate of major peri-operative complications (Clavien-Dindo grade
III or higher, please see appendix A) that occur within 90 days after cytoreductive
prostatectomy.
1) time to PSA nadir and 2) time to rising PSA while on standard systemic therapy.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Maneuver |
Patients deemed to have cT3 or less will be offered the Robotic Assisted Radical Prostatectomy (RARP).
20 | years-old | <= |
Not applicable |
Male
1 Histologically proven adenocarcinoma of the prostate.
2 Evidence of lymph node or bone metastasis by MRI/CT, bone scan, or biopsy
(N1Mx or NxM1).
3 Give informed consent.
4 Clinical stage T3 or less (pelvic MRI or CT scan shows no rectal and ureteral
invasion).
5 Must be male and 18 years or older
6 Cleared by the primary medical doctor for surgery.
7 ECOG Performance Status of 0 or 1.
1 Males under the age of 20.
2 Refuses to give informed consent.
3 Refuses or is unable to have pelvic MRI or CT scan.
4 Clinical stage T4 (pelvic MRI shows rectal and/or ureteral invasion).
5 Deemed a poor surgical risk per primary medical doctor.
6 Known spinal cord compression or brain or liver metastasis or any other visceral
metastases.
7 DVT/PE in the past 6 months
10
1st name | Shigeo |
Middle name | |
Last name | Horie |
Juntendo University Hospital
Dept. of Urology
1138431
3-1-3 Hongo Bunkyo-ku, Tokyo, Japan
+81-3-3813-3111
shorie@juntendo.ac.jp
1st name | Masayoshi |
Middle name | |
Last name | Nagata |
Juntendo University Hospital
Dept. of Urology
1138431
3-1-3 Hongo Bunkyo-ku, Tokyo, Japan
+81-3-5802-1227
m-nagata@juntendo.ac.jp
Juntendo University, Graduate School of Medicine
health insurance
Other
Rutgers Cancer Institute of New Jersey, University of Pennsylvania (Philadelphia, PA), Temple University (Philadelphia, PA), City of Hope (Duarte, CA), University of California at Irvine (Orange, CA),
Swedish Medical Center (Seattle, WA), Seoul National University Bundang Hospital (Seoul, Korea)
Juntendo University Ethics Committee
3-1-3 Hongo Bunkyo-ku, Tokyo, Japan
03-3813-3111
jun-rinri@juntendo.ac.jp
NO
Rutgers Cancer Institute of New Jersey, University of Pennsylvania (Philadelphia, PA), Temple University (Philadelphia, PA), City of Hope (Duarte, CA), University of California at Irvine (Orange, CA), Swedish Medical Center (Seattle, WA), Seoul National University Bundang Hospital (Seoul, Korea)
2016 | Year | 04 | Month | 01 | Day |
Unpublished
Completed
2016 | Year | 01 | Month | 20 | Day |
2020 | Year | 01 | Month | 31 | Day |
2016 | Year | 04 | Month | 01 | Day |
2018 | Year | 12 | Month | 31 | Day |
2016 | Year | 03 | Month | 02 | Day |
2020 | Year | 08 | Month | 20 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024520